{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:21:57Z","timestamp":1772770917288,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Radium-223 dichloride (Ra-223) is recommended as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral disease, after docetaxel failure, or in patients who are not candidates to receive it. In this study, we aimed to ambispectively analyze overall survival (OS) and prognostic features in mCRPC in patients receiving Ra-223 as per clinical routine practice and identify the most suitable treatment sequence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>This study is observational, multicentric, and ambispective. Eligibility criteria included mCRPC patients treated with Ra-223, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0\u20132, without visceral metastases, and no more than three cm involved lymph nodes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 145 patients were included; the median age was 73.97 years, and a Gleason score of more than or equal to 7 in 61 (48%) patients; 73 (81%) had previously received docetaxel. The most important benefit was reached by those patients who received Ra-223 in the second-line setting, with a median OS of 17 months (95% CI, 12\u201321), and by patients who received six cycles of treatment, with a median OS of 19 months (95% CI, 14\u201321). An alkaline phosphatase (ALP) decrease was also identified as a prognosis marker. When performing the multivariate analysis, the time to develop castration-resistant disease longer than 24 months was the most important prognostic factor to predict the evolution of the patients receiving Ra-223. Ra-223 was well tolerated, with thrombocytopenia, anemia, and diarrhea being the main adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There is a benefit for those patients who received Ra-223 in the second-line setting, regardless of prior use of docetaxel. In addition, a survival benefit for patients presenting with a decline in ALP was observed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1385466","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T04:30:42Z","timestamp":1715056242000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Urbano","family":"Anido-Herranz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovidio","family":"Fernandez-Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ruiz-Ba\u00f1obre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Martinez-Breijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Fernandez-Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulema","family":"Nogareda-Seoane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Garrido-Pumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Casas-Nebra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Mu\u00f1iz-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Portela-Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gomez-Caama\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Adolfo","family":"Perez-Fentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Santome-Couto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurea","family":"Molina-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Medina-Colmenero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Vazquez-Estevez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221775","article-title":"Global incidence of prostate cancer in developing and developed countries with changing age structures","volume":"14","author":"Teoh","year":"2019","journal-title":"PloS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13493970","article-title":"Health care costs for state transition models in prostate cancer","volume":"34","author":"Krahn","year":"2014","journal-title":"Med Decis Making"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2015.999045","article-title":"Radium-223 dichloride: A new paradigm in the treatment of prostate cancer","volume":"15","author":"Anido Herranz","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223ra: adjuvant or alternative to conventional modalities","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw065","article-title":"Patient-reported quality-of-life analysis of radium-223 dichloride from the phase iii alsympca study","volume":"27","author":"Nilsson","year":"2016","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.09.035","article-title":"The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: exploratory analyses of affirm and prevail studies","volume":"87","author":"Beer","year":"2017","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the cou-aa-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase iii trial-firstana","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (Propel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase iii magnitude trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (Talapro-2): A randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.remn.2019.04.004","article-title":"Four years of clinical experience with radium-223 for the treatment of castration-resistant prostate cancer","volume":"38","author":"\u00c1lvarez P\u00e9rez","year":"2019","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2217\/fon-2017-0297","article-title":"Radium-223 international early access program: results from the spanish subset","volume":"14","author":"Carles","year":"2018","journal-title":"Future Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.06.057","article-title":"Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase ii trial","volume":"173","author":"Carles","year":"2022","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23893","article-title":"Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1\/2 study in patients with castration-resistant prostate cancer and bone metastases","volume":"79","author":"Sartor","year":"2019","journal-title":"Prostate"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (Era 223): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.003","article-title":"The case against the european medicines agency's change to the label for radium-223 for the treatment of metastatic castration-resistant prostate cancer","volume":"75","author":"O'Sullivan","year":"2019","journal-title":"Eur Urol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23180","article-title":"Chemotherapy following radium-223 dichloride treatment in alsympca","volume":"76","author":"Sartor","year":"2016","journal-title":"Prostate"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.09.002","article-title":"Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden","volume":"21","author":"Stattin","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx044","article-title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 alsympca trial with radium-223","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.09.015","article-title":"Prospective assessment of bone metabolism biomarkers and survival in metastatic castration-resistant prostate cancer patients treated with radium-223: the proradium study","author":"Romero-Laorden","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1130-1","article-title":"Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases","volume":"22","author":"Uemura","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17311","article-title":"Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy","volume":"8","author":"Wenter","year":"2017","journal-title":"Oncotarget"},{"key":"B35","article-title":"Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival","volume":"31","author":"Bournakis","year":"2011","journal-title":"Anticancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.03.021","article-title":"The effect of time to castration resistance on outcomes with abiraterone and enzalutamide in metastatic prostate cancer","volume":"14","author":"Hung","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.128","article-title":"Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer","volume":"51","author":"Loriot","year":"2015","journal-title":"Eur J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000434","article-title":"Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate","volume":"28","author":"Giacinti","year":"2017","journal-title":"Anticancer Drugs"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.22037\/uj.v0i0.4497","article-title":"The effect of time to castration resistance on overall survival and success of docetaxel treatment in castration resistant prostate cancer patients","volume":"16","author":"Suer","year":"2019","journal-title":"Urol J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"iv35","DOI":"10.1093\/annonc\/mdw334.19","article-title":"Analysis of overall survival by number of radium-223 injections received in an international expanded access program (Ieap)","volume":"27","author":"Paganelli","year":"2016","journal-title":"Ann Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5203-y","article-title":"Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program","volume":"19","author":"Heidenreich","year":"2019","journal-title":"BMC Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2017-0413","article-title":"Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. Experience from an expanded access program","volume":"23","author":"Sartor","year":"2018","journal-title":"Oncologist"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101993","article-title":"Clinical outcomes and treatment patterns in reassure: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer","volume":"60","author":"Higano","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1385466\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T04:30:49Z","timestamp":1715056249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1385466\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":43,"alternative-id":["10.3389\/fonc.2024.1385466"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1385466","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"article-number":"1385466"}}